INTRODUCTION
∆*-Tetrahydrocannabinol (THC), the main active component of marijuana (Cannabis sati a), and other cannabinoids exert a wide spectrum of central and peripheral effects, such as alterations in cognition and memory, analgesia, anti-convulsion, anti-inflammation and alleviation of both intraocular pressure and emesis [1, 2] . Cannabinoids produce their effects by binding to specific plasma membrane G-protein-coupled receptors [1, 2] . To date, two different cannabinoid receptors have been cloned and characterized from mammalian tissues, CB " [3] and CB # [4] . Activation of these receptors has been shown to trigger several G i/o -protein-mediated signalling pathways. For example, both CB " and CB # receptors induce the inhibition of adenylate cyclase and stimulation of extracellular-signal-regulated kinase (ERK), and the CB " receptor is also coupled to modulation of Ca# + and K + channels [1, 2] . The recent discovery of a family of endogenous ligands of cannabinoid receptors [5, 6] has focused much attention on cannabinoids over the last few years. In addition, the renaissance in the study of the therapeutic effects of cannabinoids constitutes a widely debated issue with ample scientific and social relevance. Ongoing research is determining whether cannabinoid ligands may be effective agents in the treatment of pain, glaucoma, multiple sclerosis and the wasting and emesis associated with AIDS and cancer chemotherapy [7, 8] . Cannabinoids might also be potential antitumoral agents, owing to their ability to inhibit the growth of various types of cancer cells in culture [9] [10] [11] [12] . Moreover, in laboratory animals, cannabinoids induce the regression of gliomas, one of the most malignant forms of cancer [13] . This growth-inhibiting effect was exerted by THC and WIN-55,212-2, a synthetic cannabinoid agonist, and was mediated by cannabinoid receptor activation and ceramide generation [13] .
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However, no major changes in SPT mRNA and protein levels were evident. Changes in SPT activity paralleled changes in ceramide levels. Pharmacological inhibition of ceramide synthesis de no o also prevented the stimulation of extracellular-signalregulated kinase and the inhibition of protein kinase B triggered by cannabinoids. These findings show that de no o-synthesized ceramide is involved in cannabinoid-induced apoptosis of glioma cells.
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Ceramide is a sphingosine-based lipid that regulates a variety of cellular processes, including differentiation, proliferation and apoptosis [14] [15] [16] . Accumulation of ceramide has been usually considered to occur via receptor-mediated activation of neutral or acid sphingomyelinases. However, over the last few years, the de no o synthesis pathway has been gaining appreciation as an alternative means of generating a signalling pool of ceramide [15, 16] . We have shown previously [13] that exposure of glioma cells to cannabinoids triggers the generation of two peaks of ceramide. The first peak, occurring within minutes of the cannabinoid treatment, may involve neutral sphingomyelinase stimulation via the adaptor protein FAN [17, 18] , and does not play a significant role in the induction of apoptosis [13] . The second peak of ceramide starts at day 3 of cannabinoid treatment, reaching a maximum by day 5, and has been closely related to the apoptotic death of glioma cells [13] . However, the mechanism by which cannabinoids generate this sustained peak of ceramide is, as yet, unknown. The present study was therefore undertaken to investigate how this pro-apoptotic second peak of ceramide is generated in glioma cells, and whether this ceramide pool modulates ERK and protein kinase B (PKB).
EXPERIMENTAL

Glioma cell culture and viability
The rat glioma C6 line (10-20 passages) was cultured as described previously [10] . Two subclones of C6 glioma cells, which have been previously characterized in terms of cannabinoid-induced apoptosis, were used in this study : the C6.9 subclone, which is sensitive to THC-induced apoptosis, and the C6.4 subclone, which is resistant to THC-induced apoptosis [13] . Cell viability was determined by Trypan Blue exclusion. THC stock solutions were prepared in DMSO and control incubations contained the same amount of DMSO. No significant effect of DMSO was observed in any of the parameters determined throughout this study at the final concentration used (0.1-0.2 %, v\v).
Terminal deoxynucleotidyltransferase-mediated dUTP nick-end labelling (TUNEL) staining
C6 glioma cells were washed with PBS, fixed for 20 min at 20 mC in PBS\4 % paraformaldehyde\5 % (w\v) sucrose, permeabilized with 0.05 % Triton-X-100\PBS for 5 min, and blocked with 0.5 % BSA\PBS for 30 min. DNA ends were subsequently labelled for 2 h at 37 mC in Tris-buffered saline [TBS : 50 mM Tris\HCl (pH 7.2) and 100 mM NaCl] containing 2 mM CoCl # , 0.1 unit\µl terminal deoxynucleotidyl transferase (Life Technologies, Paisley, Renfrewshire, Scotland, U.K.) and 2.5 pmol\µl biotin-16-dUTP (Boehringer Mannheim, Mannheim, Germany). Finally, cells were incubated for an additional 2 h with 3.5 µg\ml streptavidin-Alexa2Fluor 488 (Molecular Probes, Leiden, The Netherlands) in 0.1 % BSA\PBS.
Ceramide levels
Ceramide levels were determined as described previously [19] . Briefly, after incubation of the cells in the different conditions, lipids were extracted, saponified, and incubated with Escherichia coli diacylglycerol kinase in the presence of [γ-$#P]ATP. Finally, ceramide 1-phosphate was resolved by TLC.
ERK activity and levels
Cells were washed, lysed, supernatants were obtained, and ERK activity was determined via the incorporation of [γ-$#P]ATP into APRTPGGRR (where single-letter amino-acid notation has been used), a specific peptide substrate, as described previously [20] . ERK protein levels were determined by Western-blot analysis with an antibody that recognizes both the phosphorylated and non-phosphorylated form of ERK (New England Biolabs, Beverly, MA, U.S.A.).
PKB activity and levels
PKB activity was determined as described previously [21] . Briefly, PKB was immunoprecipitated from cell lysates with 2 µg of anti-PKBα antibody bound to Protein G-Sepharose. Kinase activity was determined via the incorporation of [γ-$#P]ATP into GRPRTSSFAEG (where single-letter amino-acid notation has been used), a specific peptide substrate. PKB protein levels were determined by Western-blot analysis with an antibody that recognizes both the phosphorylated and non-phosphorylated form of PKB.
Serine palmitoyltransferase (SPT) assay
SPT activity was determined in digitonin-permeabilized C6 glioma cells via the incorporation of radiolabelled -serine into ketosphinganine by using a new procedure [22] with minor modifications. Briefly, the medium was aspirated and cells were washed twice with PBS. Reactions were started by the addition of 100 mM Hepes (pH 8.3)\200 mM sucrose\2.5 mM EDTA\ 5 mM dithioerythritol\50 µM pyridoxal phosphate\ 1.0 mg\ml BSA\8.75 µg\ml digitonin\0.3 mM palmitoyl-CoA\0.25 mM -[U-"%C]serine (3 µCi\assay). After 30 min, reactions were stopped with 0.5 M NH % OH, the ["%C]ketosphinganine product was extracted with chloroform\methanol (2 : 1, v\v), and the organic phases were subsequently washed with 1 % (w\v) NaCl.
Preliminary experiments defined the optimal concentration of digitonin and other reagents in the assay, as well as its linearity with time.
Western-blot analysis of SPT
Western-blot analysis was carried out with polyclonal antibodies raised against hamster SPT long-chain base subunit (LCB) 1 and LCB2 [22, 23] . Briefly, cells were lysed, and samples were subjected to centrifugation at 12 000 g for 1 h at 4 mC. Pellets were resuspended in lysis buffer [21] , 50 µg of total protein from each sample was subjected to SDS\PAGE on 10 % (w\v) gels, and proteins were transferred on to nitrocellulose membranes [21] . The blots were blocked with TBS\0.1 % Tween-20\5 % (w\v) non-fat dried milk and incubated with anti-(LCB1) or anti-(LCB2) antibodies [1 : 150 dilution in TBS\0.1 % Tween-20\5 % (w\v) non-fat dried milk]. Finally, membranes were subjected to luminography with an enhanced chemiluminescence detection kit (Amersham Biosciences, Little Chalfont, Bucks., U.K.).
Northern-blot analysis of SPT
For RNA preparation, cells were washed with ice-cold PBS and total RNA was extracted using the RNAgents total RNA extraction kit (Promega, Madison, U.S.A.). Briefly, 30 µg of total cellular RNA was separated on 37 % formaldehyde-containing 1.2 % agarose gels and transferred on to nylon membranes (Roche, Basel, Switzerland). After prehybridization for 8 h at 42 mC in 5iSSC (1iSSC is 0.15 M NaCl\15 mM sodium citrate)\50 % formamide\0.1 % laurosyl sarcosine\0.2 % SDS\2 % blocking reagent (Roche, Basel, Switzerland), membranes were incubated with cDNA fragments labelled by random primers in the presence of [α-$#P]dATP. The probes were an 867 bp SmaI fragment of human LCB1 and a 747 bp HindIII\ScaI fragment of human LCB2, obtained from digestion of plasmids encoding LCB1 and LCB2 of SPT [24] . Membranes were subsequently washed twice with 2iSSC\0.1 % SDS (5 min at 20 mC) ; twice with 0.2iSSC\0.1 % SDS (15 min at 42 mC) ; and once with 0.2iSSC\0.1 % SDS (15 min at 55 mC). Blots were exposed finally to Kodak X-AR films with intensifier screens at k70 mC.
Statistics
Results shown represent meanspS.D. Statistical analysis was performed by ANOVA with a post hoc analysis by the StudentNeuman-Keuls test.
RESULTS
Inhibition of ceramide synthesis de novo prevents THC-induced ceramide accumulation and apoptosis
Treatment of C6 glioma cells with THC and other cannabinoids has been shown to induce apoptosis via ceramide generation [13] . However, the metabolic origin of the ceramide pool responsible for cannabinoid-induced apoptosis remains unknown. Two major pathways may contribute to intracellular ceramide accumulation : sphingomyelin hydrolysis and ceramide synthesis de no o [14, 15] . Hence we tested whether selective pharmacological inhibitors of those two pathways [16, [25] [26] [27] [28] were able to prevent cannabinoid-induced apoptosis of C6 glioma cells. As shown in Figure 1 , none of desipramine (an inhibitor of acid sphingomyelinase), scyphostatin (an inhibitor of neutral sphingomyelinase) or PMA (which inhibits neutral sphingomyelinase via protein kinase C activation) prevented THC-induced death of C6.9 glioma cells. In contrast, blockade of ceramide synthesis de no o with -cycloserine (an inhibitor of SPT) or fumonisin B " (an inhibitor of ceramide synthase) prevented THC-induced death of C6.9 glioma cells (Figures 1 and 2 ). To confirm that ceramide synthesis de no o is involved in THC-induced ceramide accumulation and cell death, we determined ceramide levels and cell viability in parallel. -Cycloserine prevented not only THC-induced death of C6.9 glioma cells (Figure 2A ), but also THC-induced long-term ceramide accumulation in these cells (Figure 3) . A good relationship was observed between the kinetics of cell death and that of ceramide levels, although at day 3 of treatment there was significant cell death (Figure 2A ), but only slight ceramide accumulation (Figure 3) . TUNEL-staining analysis was performed to test whether THCinduced apoptosis of C6.9 glioma cells occurs by apoptosis. As shown in Figure 2 (B), TUNEL-positive nuclei were evident upon THC treatment, and this effect was efficiently prevented by -cycloserine.
THC enhances SPT activity without major changes in its mRNA and protein levels
Because SPT catalyses the rate-limiting step of ceramide synthesis de no o [28] , we determined whether ceramide accumulation correlated with SPT activity during the treatment with THC. As shown in Figure 4 (A), incubation of C6.9 glioma cells with THC enhanced SPT activity in parallel with ceramide accumulation (Figure 3) . A good relationship was also observed between the kinetics of cell death and that of SPT activity, although, as mentioned above for ceramide levels, at day 3 of treatment there was significant cell death (Figure 2A ), but only slight SPT activation ( Figure 4A ). Of interest, SPT activation was not observed in C6.4 glioma cells ( Figure 4A ), a subclone of C6 glioma cells in which THC does not induce apoptosis ( Figure  2A ) and ceramide accumulation (Figure 3 ) [13] .
To test whether THC enhances SPT activity by inducing SPT expression, enzyme mRNA and protein levels were monitored by Northern and Western blot respectively. As shown in Figure   Figure 
4(B)
, the levels of the regulatory LCB1 were only slightly enhanced in C6.9 glioma cells after THC challenge (1.8p0.4 fold increase, n l 3; P 0.05 compared with incubations with no additions). In addition, no significant changes in the levels of LCB1 in C6.4 cells and the catalytic LCB2 in the two subclones were evident upon THC treatment ( Figure 4B and results not shown). Likewise, THC did not significantly increase the mRNA levels of either SPT subunits in C6.9 cells (1.4p0.4-and 1.1p0.3-fold increase for LCB1 and LCB2 respectively, n l 3; not significantly different than incubations with no additions) ( Figure 4C ).
De novo-synthesized ceramide activates ERK and inhibits PKB
Ceramide-induced apoptosis may be mediated, at least in part, via modulation of the ERK [14] and PKB [29] signalling pathways. In particular, we have shown previously that sustained ERK activation may contribute to ceramide-induced apoptosis in C6 glioma cells [13] and primary astrocytes [30] . Therefore we studied the contribution of de no o-synthesized ceramide in the regulation of ERK and PKB in C6.9 and C6.4 glioma cells. Blockade of ceramide synthesis de no o with -cycloserine 
DISCUSSION
Origin of pro-apoptotic ceramide
One of the areas of current cannabinoid research is focused on the ability of these compounds to control the cell survival\death decision. Thus cannabinoids may induce proliferation, growth arrest or apoptosis in a number of cells, including neurons, lymphocytes and various transformed neural and non-neural cells [31] . Upon THC challenge, two peaks of ceramide are generated in C6 glioma cells [13] . In the present study, we show that the pro-apoptotic sustained peak of ceramide is generated by the stimulation of SPT and the de no o synthesis pathway. Although it has been usually considered that ceramide generation through sphingomyelin hydrolysis is the norm in ceramide signalling pathways [14, 15] , over the last few years long-term ceramide accumulation through enhanced de no o synthesis has been gaining appreciation as an alternative means of generating a pro-apoptotic pool of this compound in neural [22, 30, 32, 33] and non-neural cells [25, [34] [35] [36] [37] . However, the mechanisms that regulate SPT activity are still a matter of controversy. For example, Weiss and Stoffel [38] showed that overexpression of the catalytic LCB2 is sufficient to enhance the activity of the enzyme, whereas Hanada et al. [39] observed that LCB1 is essential for the activity of the enzyme. Likewise, Farrell et al. [40] observed that LCB2 protein and mRNA levels are upregulated in human keratinocytes in response to UV-B, whereas other reports have shown that the stimulation of SPT activity in response to different pro-apoptotic stimuli occurs without changes in the levels of SPT protein [33, 37] . Our present data clearly support the notion that, besides changes in enzyme levels, post-translational mechanisms may be involved in the control of SPT activity. We are currently studying the molecular basis of these mechanisms.
Ceramide targets
The precise mechanism by which ceramide controls cell fate is still a matter of debate. Ceramide has been implicated in stimulation of, among other targets, ERK, c-Jun N-terminal kinase (' JNK ') and p38 mitogen-activated protein kinase cascades, several protein kinase C isoforms, kinase suppressor of Ras, and a ceramide-activated protein phosphatase [14] [15] [16] . In addition, ceramide inhibits PKB [29] . Our present results, together with previous observations [13] , indicate that long-term ceramide accumulation may be involved in apoptosis of C6.9 glioma cells by activating ERK and inhibiting PKB. A large body of evidence supports the implication of both signalling pathways in the control of neural-cell fate. Thus inhibition\lack of stimulation of the phosphoinositide 3-kinase\PKB route in neural cells may lead to apoptosis [41] . In addition, although the ERK cascade has been traditionally considered as mediating cell proliferation rather than apoptosis [41] , it has been reported recently that sustained ERK activation may mediate cell-cycle arrest and apoptosis in neural cells [30, [42] [43] [44] . Nevertheless, it should be noted that in C6.9 glioma cells, cannabinoids, besides activating ERK and inhibiting PKB, also mediate c-Jun N-terminal kinase and p38 mitogen-activated protein kinase activation [13] . In addition, we are aware that the time of glioma cell death observed in the present study is somewhat earlier than the time of SPT activation and ceramide generation. Hence, cannabinoid-induced apoptosis of glioma cells may depend on the cross-talk among the different pathways that would be affected by cannabinoid challenge, rather than the modulation of a single signalling route.
Therapeutic potential
The antitumoral action of cannabinoids on gliomas is mediated by cannabinoid receptors [13] . Of importance, recent data from our laboratory have shown that selective CB # agonists, which are devoid of typical CB " receptor-mediated psychotropic sideeffects, produce the same antitumoral actions as their nonselective counterparts through a mechanism that is also dependent on ceramide accumulation (C. Sa! nchez, T. Go! mez del Pulgar, G. Velasco and M. Guzma! n, unpublished work). In agreement with a pathophysiological role for de no o-synthesized ceramide in the control of neural cell fate, hereditary sensory neuropathy I, the most common hereditary disorder of peripheral sensory neurons, occurs via activating mutations in the gene that encodes LCB1 of SPT [45, 46] . These mutations would lead in turn to enhanced apoptosis of neurons via ceramide synthesis de no o. Of interest, cannabinoids, in line with their suggested neuroprotective role [8] , do not induce apoptosis or sustained ceramide accumulation in primary neurons and astrocytes [18] . Therefore a potential cannabinoid therapy for the treatment of malignant gliomas could be on the basis of the ability of these compounds to selectively stimulate ceramide synthesis de no o and apoptosis in transformed glial cells, but not in non-transformed neural cells.
